Compare DraftKings Inc (DKNG) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DraftKings Inc vs Sanofi SA — how do they compare? DraftKings Inc trades at $25.59 (market cap $12.58B), while Sanofi SA trades at $43.4 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 8.3× DraftKings Inc's market cap, and Sanofi SA pays a 5.55% dividend while DraftKings Inc pays none. Which is the better fit depends on your goals.
| DKNG | SNY | |
|---|---|---|
Market Cap | $12.58B | $104.30B |
Sector | Consumer Cyclical | Health |
52-Week High | $48.23 | $52.34 |
52-Week Low | $20.72 | $41.33 |
Enterprise Value | $13.51B | $124.19B |
Dividend Yield | — | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DraftKings (DKNG) trades at $25.79, up 6.24% on the day, with a bullish technical signal and strong analyst consensus. Revenue grew to $6.05 billion in 2025, though recent quarters show earnings misses. The company is expanding into prediction markets, with CEO Jason Robins highlighting rapid growth ahead of the NFL season (Bloomberg Technology, 2026-08-07).
The outlook is mixed: strong revenue growth and positive cash flow from operations contrast with high valuation multiples and recent profitability challenges. Key risks include competition from prediction markets and promotional costs pressuring margins. The consensus price target of $34.00 suggests upside potential if execution improves.
SNY trades at $43.62, up 0.32% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 outlook. Revenue for 2025 was $46.72B with net income of $7.81B, showing improved profitability. Analyst consensus is mixed with 44% Buy, 52% Hold, and 4% Sell ratings. Recent news highlights regulatory approvals for new drugs and pipeline developments under new CEO leadership.
The outlook for SNY is cautiously optimistic, driven by Dupixent's growth and new drug approvals, but faces risks from pipeline setbacks and competition. Earnings momentum and cost discipline support upside potential, though valuation multiples like a P/E of 23.27 may limit near-term gains. Key risks include biosimilar threats post-2031 and ongoing legal challenges. Institutional activity shows increased holdings, reflecting confidence in the company's strategic direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DraftKings Inc
DraftKings Inc is a digital sports entertainment and gaming company. The company provides users with daily fantasy sports (DFS), sports betting, and iGaming opportunities and is also involved in the design & development of sports betting and casino gaming platform software for online and retail sportsbook and casino gaming products. It operates in two segments: Business-to-consumer(B2C) and Business-to-Business(B2B), of which the vast majority of its revenue comes from the B2C segment. Geographically, it derives most of its revenue from the United States.
Read more on DKNG →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
